Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTT-121 SAD/MAD in Healthy Chinese Subjects
NCT07768176Phase 1Recruiting
- Sponsor
- Pyrotech Therapeutics
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing PTT-121 treatment with Placebo treatment (2 arms). Primary endpoint: Treatment-emergent Adverse Events at 21 days. Started Aug 2026; status: recruiting.
02
Drugs
PTT-121
Beyond the preview
Go deeper on NCT07768176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768176.